Zobrazeno 1 - 10
of 107
pro vyhledávání: '"William T, Symonds"'
Autor:
David R. Nelson, Mark S. Sulkowski, John G. McHutchison, Stefan Zeuzem, Ira M. Jacobson, Edward Gane, Rafael Esteban, Diana M. Brainard, Eric Lawitz, Douglas T. Dieterich, John McNally, William T. Symonds
Publikováno v:
Annals of the New York Academy of Sciences. 1358:56-67
The nucleotide analog NS5B polymerase inhibitor sofosbuvir was approved by the U.S. Food and Drug Administration (FDA) in December 2013 for the treatment of chronic hepatitis C virus (HCV) infection in combination with ribavirin or peginterferon and
Publikováno v:
Clinical Pharmacokinetics. 54:677-690
Sofosbuvir (SOVALDI(®)), a potent, once-daily, orally administered nucleotide analog prodrug inhibitor of the hepatitis C virus (HCV) NS5B polymerase is approved in the USA, EU, Canada, and other regions for the treatment of HCV infection as a compo
Autor:
Jill Denning, Xavier Forns, Paul Chang, Diana M. Brainard, William T. Symonds, Thomas F. Baumert, John G. McHutchison, Valerie Kivett, Theo S. Brandt-Sarif, François Habersetzer, Martín Prieto, Michael Charlton, Lluis Castells, Audrey Coilly, Robert J. Fontana, María-Carlota Londoño
Publikováno v:
HEPATOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Hepatology
Hepatology, Wiley-Blackwell, 2015, 61 (5), pp.1485-1494. ⟨10.1002/hep.27681⟩
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Hepatology
Hepatology, Wiley-Blackwell, 2015, 61 (5), pp.1485-1494. ⟨10.1002/hep.27681⟩
Recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) is associated with accelerated progression of liver disease, frequently leading to graft loss and early death. Existing treatment options for severe recurrent HCV infection
Autor:
Xavier Forns, John G. McHutchison, Diana M. Brainard, William T. Symonds, Norah A. Terrault, Robert S. Brown, Sarah Arterburn, Paul Y. Kwo, Robert J. Fontana, Michael P. Manns, Andrew J. Muir, Brian J. Kirby, Michael Charlton, Lewis W. Teperman, Didier Samuel, Hadas Dvory-Sobol, Jill Denning, Richard Gilroy, Edward Gane, Michael P. Curry
Publikováno v:
Gastroenterology. 148:108-117
Background & Aims Interferon alfa–based regimens used to treat recurrent hepatitis C virus (HCV) infection after liver transplantation are poorly tolerated, associated with generally modest efficacy, and can interact with immunosuppressive agents.
Autor:
Julie Ma, John McNally, Robert Herring, Vlad Ratziu, William T. Symonds, Luisa M. Stamm, Eric Lawitz, Diana M. Brainard, Jing Wang, Kimberly L. Beavers, Eric M. Yoshida, Mark S. Sulkowski, Xiao Ding, John G. McHutchison, Ira M. Jacobson, K. Rajender Reddy, Edward Gane, Shu Min Chuang
Publikováno v:
Hepatology. 61:41-45
Historically, clinical trials of regimens to treat chronic infection with hepatitis C virus (HCV) have used, as their primary efficacy endpoint, a sustained virological response (SVR)—defined as HCV RNA levels below a designated threshold of quanti
Autor:
Brian L. Pearlman, Joseph K. Lim, Reem Ghalib, John D. Scott, Katleen Callewaert, Ana Corregidor, Sivi Ouwerkerk-Mahadevan, Karen L Lindsay, Ira M. Jacobson, Eric Lawitz, Zobair M. Younossi, Gaston Picchio, Mark S. Sulkowski, Paul J. Pockros, Norman Gitlin, Maria Beumont, Maribel Rodriguez-Torres, Edwin DeJesus, William T. Symonds, Bart Fevery, Tom Lambrecht, Mordechai Rabinovitz
Publikováno v:
The Lancet. 384:1756-1765
Summary Background Interferon-free regimens are needed to treat hepatitis C virus (HCV) infections. We investigated the efficacy of combined simeprevir and sofosbuvir. Methods We enrolled patients with chronic HCV genotype 1 infections who had previo
Autor:
Mikio Yanase, Diana M. Brainard, Takeji Umemura, Steven J. Knox, Hadas Dvory-Sobol, Tetsuo Takehara, Yoshiyuki Ueno, Masa Omote, Kimberly L. Garrison, Takuya Genda, Bing Gao, Naoya Sakamoto, Masao Omata, Masashi Mizokami, Hitoshi Mochizuki, Kazushige Nirei, William T. Symonds, Hidenori Toyoda, Osamu Yokosuka, Namiki Izumi, Akinobu Ishizaki, Tatsuya Ide, Keisuke Hino, John G. McHutchison, Shuhei Nishiguchi, Yoichi Nishigaki, Hiroshi Yatsuhashi, Nobuo Toda, Fusao Ikeda, Kunio Nakane
Publikováno v:
Journal of Viral Hepatitis. 21:762-768
Genotype 2 hepatitis C virus (HCV) accounts for up to 30% of chronic HCV infections in Japan. The standard of care for patients with genotype 2 HCV - peginterferon and ribavirin for 24 weeks - is poorly tolerated, especially among older patients and
Autor:
Nezam, Afdhal, K Rajender, Reddy, David R, Nelson, Eric, Lawitz, Stuart C, Gordon, Eugene, Schiff, Ronald, Nahass, Reem, Ghalib, Norman, Gitlin, Robert, Herring, Jacob, Lalezari, Ziad H, Younes, Paul J, Pockros, Adrian M, Di Bisceglie, Sanjeev, Arora, G Mani, Subramanian, Yanni, Zhu, Hadas, Dvory-Sobol, Jenny C, Yang, Phillip S, Pang, William T, Symonds, John G, McHutchison, Andrew J, Muir, Mark, Sulkowski, Paul, Kwo, Ziad, Younes
Publikováno v:
New England Journal of Medicine. 370:1483-1493
Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients who have not had a sustained virologic response to prior interferon-based therapy represents an unmet medical need.We conducted a phase 3, randomized, open-label study i
Autor:
Jill Denning, Jeremie Guedj, Alan S. Perelson, William T. Symonds, Phillip S Pang, Eric Lawitz, Maribel Rodriguez-Torres
Publikováno v:
Antiviral Therapy. 19:211-220
Background Sofosbuvir (GS-7977) and GS-0938 are nucleotide analogue HCV polymerase inhibitors, with sofosbuvir being a pyrimidine and GS-0938 being a purine. Mathematical modelling has provided important insights for characterizing HCV RNA decline an
Autor:
Gregory T. Everson, Dennis Hernandez, K. Rajender Reddy, Dennis M. Grasela, Maribel Rodriguez-Torres, Paul J. Thuluvath, David R. Nelson, Min Gao, Federico Hinestrosa, William T. Symonds, Anna S. Lok, Eric Lawitz, David F. Gardiner, Claudio Pasquinelli, Fiona McPhee, Diane Sherman, Megan Wind-Rotolo, R. Hindes, Shu-Pang Huang, Timothy Eley, Tarek Hassanein, Ira M. Jacobson, Mark S. Sulkowski, Howard J. Schwartz
Publikováno v:
New England Journal of Medicine. 370:211-221
All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analogue HCV NS5B polymerase inhibitor) in patie